| CRISPR-engineered T cells in patients with refractory cancer EA Stadtmauer, JA Fraietta, MM Davis, AD Cohen, KL Weber, E Lancaster, ... Science 367 (6481), eaba7365, 2020 | 1342 | 2020 |
| Directed evolution of CRISPR-Cas9 to increase its specificity JK Lee, E Jeong, J Lee, M Jung, E Shin, Y Kim, K Lee, I Jung, D Kim, ... Nature communications 9 (1), 3048, 2018 | 532 | 2018 |
| PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial V Narayan, JS Barber-Rotenberg, IY Jung, SF Lacey, AJ Rech, MM Davis, ... Nature medicine 28 (4), 724-734, 2022 | 318 | 2022 |
| CRISPR/Cas9-mediated knockout of DGK improves antitumor activities of human T cells IY Jung, YY Kim, HS Yu, M Lee, S Kim, J Lee Cancer research 78 (16), 4692-4703, 2018 | 196 | 2018 |
| BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia W Kong, A Dimitri, W Wang, IY Jung, CJ Ott, M Fasolino, Y Wang, ... The Journal of clinical investigation 131 (16), 1-16, 2021 | 73 | 2021 |
| BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion IY Jung, V Narayan, S McDonald, AJ Rech, R Bartoszek, G Hong, ... Science translational medicine 14 (670), eabn7336, 2022 | 67 | 2022 |
| Unleashing the therapeutic potential of CAR-T cell therapy using gene-editing technologies IY Jung, J Lee Molecules and cells 41 (8), 717-723, 2018 | 60 | 2018 |
| FOXO1 is a master regulator of memory programming in CAR T cells AE Doan, KP Mueller, AY Chen, GT Rouin, Y Chen, B Daniel, J Lattin, ... Nature, 1-8, 2024 | 54 | 2024 |
| Simultaneous conversion of glucose and xylose to 3-hydroxypropionic acid in engineered Escherichia coli by modulation of sugar transport and glycerol synthesis IY Jung, JW Lee, WK Min, YC Park, JH Seo Bioresource technology 198, 709-716, 2015 | 52 | 2015 |
| Tissue-resident memory CAR T cells with stem-like characteristics display enhanced efficacy against solid and liquid tumors IY Jung, E Noguera-Ortega, R Bartoszek, SM Collins, E Williams, M Davis, ... Cell Reports Medicine 4 (6), 2023 | 32 | 2023 |
| Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction IY Jung, RL Bartoszek, AJ Rech, SM Collins, SK Ooi, EF Williams, ... Cancer discovery 13 (7), 1636-1655, 2023 | 17 | 2023 |
| Enhanced costimulatory signaling improves CAR T-cell effector responses in CLL MKA Collins, IY Jung, Z Zhao, K Apodaca, W Kong, S Lundh, JA Fraietta, ... Cancer research communications 2 (9), 1089-1103, 2022 | 10 | 2022 |
| Manipulated immunoregulatory element and immunity altered thereby SJ Kim, YY Kim, YU Ho-Sung, I Jung, JM Lee US Patent 12,012,598, 2024 | 7 | 2024 |
| Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer S Lundh, IY Jung, A Dimitri, A Vora, JJ Melenhorst, JK Jadlowsky, ... Clinical and Experimental Medicine 20, 469-480, 2020 | 7 | 2020 |
| FOXO1 is a master regulator of CAR T memory programming A Doan, KP Mueller, A Chen, GT Rouin, B Daniel, J Lattin, Y Chen, ... Research Square, 2023 | 3 | 2023 |
| FOXO1 is a master regulator of CAR T memory programming C Mackall, A Doan, K Mueller, A Chen, G Rouin, B Daniel, J Lattin, ... | 2 | 2023 |
| A failure to start: aborted activation of CAR T cells in chronic lymphocytic leukemia MK Collins, W Kong, I Jung, M Wang, SM Lundh, CH June, JJ Melenhorst Blood 134, 681, 2019 | 2 | 2019 |
| 247 FOXO1 is a master regulator of CAR T memory programming AE Doan, KP Mueller, A Chen, G Rouin, B Daniel, J Lattin, Y Chen, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | 1 | 2023 |
| Artificially Manipulated Immune Cell SJ Kim, YY Kim, YU Ho-Sung, I Jung, JM Lee US Patent App. 16/611,383, 2021 | 1 | 2021 |
| B-CLL mediated resistance to CAR T cell therapy via insufficient activation is CAR-independent MK Collins, W Kong, I Jung, SM Lundh, JJ Melenhorst Blood 136, 44, 2020 | 1 | 2020 |
